Abstract
Stents were introduced into clinical practice in the late 1980s. Subsequently, the Belgian Netherlands STENT and the Stent Restenosis Study trials established the “stent era” in coronary revascularization (1,2), despite an subacute thrombosis (SAT) rate of 3.7%, and more vascular bleeding complications with stents vs balloon angioplasty. Major advances in stent technologies have occurred in the past decades. Stent design has been altered to afford more flexibility, higher radial strength, lower profile, and minimal metallic coverage. Efforts are now directed at coating a stent with single or multiple bioactive antirestenosis agents, which is delivered uniformly to the underlying tissue, namely drug-eluting stents (DES). Recent clinical data (Table 1), which will be discussed in this chapter, have demonstrated the potential of these new stent technologies to become the predominant revascularization strategy in the near future. The list of promising DES technologies is long. Many of these devices were supported by sound basic science data, but only a few have proven clinical feasibility (Table 1). Based on the mechanism of action of the biological compound and its target in the restenotic process, DES were grouped as immunosuppressive, antiproliferative, anti-inflammatory, antithrombotic, and prohealing. Some agents, such as sirolimus, may affect multiple targets in the restenotic process but will be discussed under a single category.
Keywords
- Stent Thrombosis
- Bare Metal Stents
- Coronary Lesion
- Chronic Total Occlusion
- Target Lesion Revascularization
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496–501.
Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489–495.
Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the biodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003;60:172–178; discussion 179.
Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional Intravascular ultrasound study. Circulation 2001;103:192–195.
Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007–2011.
Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-stents in human coronary arteries. Circulation 2003;107:381–383.
Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773–1780.
Abizaid A, Costa MA, Blanchard D, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur Heart J 2004;25:107–112.
Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–1323.
Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (ESIRIUS). Lancet 2003;362:1093–1099.
Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24–27.
Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003;41:184–189.
Degertekin M, Lemos PA, Lee CH, et al. Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesions. Eur Heart J 2004;25:32–38.
Honda Y, Grube E, de La Fuente LM, et al. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104:380–383.
Kataoka T, Grube E, Honda Y, et al. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the study to compare restenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002;106:1788–1793.
Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38–42.
Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788–794.
Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559–564.
Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel eluting stent (ELUTES) trial. Circulation 2004;109:487–493.
Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537–1545.
Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003;107:777–784.
Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world.” The rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry. Circulation 20 2004;109:190–195
Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation 2003;107:2383–2389.
Lemos PA, Saia F, Hofma SH, et al. Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704–708.
Colombo A, Moses JW, Morice MC, et al. Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions. Circulation 2004.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this chapter
Cite this chapter
Costa, M.A., Abizaid, A., Sousa, A.G.M.R., Eduardo Sousa, J. (2007). Clinical Data of Eluting Stents. In: Duckers, H.J., Nabel, E.G., Serruys, P.W. (eds) Essentials of Restenosis. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-001-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-59745-001-0_22
Publisher Name: Humana Press
Print ISBN: 978-1-58829-491-3
Online ISBN: 978-1-59745-001-0
eBook Packages: MedicineMedicine (R0)